

**OPEN ACCESS**

## APPROVED BY

Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Ralf J. Ludwig  
ralf.ludwig@uksh.de

## †PRESENT ADDRESS

Paul Smith, Connect Biopharma, San Diego, CA, United States

<sup>‡</sup>These authors have contributed equally to this work

<sup>§</sup>These authors have contributed equally to this work

## SPECIALTY SECTION

This article was submitted to  
Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders,  
a section of the journal  
Frontiers in Immunology

RECEIVED 15 November 2022

ACCEPTED 16 November 2022

PUBLISHED 30 November 2022

## CITATION

Ghorbalalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprik A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E and Ludwig RJ (2022) Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases. *Front. Immunol.* 13:1099535. doi: 10.3389/fimmu.2022.1099535

## COPYRIGHT

© 2022 Ghorbalalipoor, Emtenani, Parker, Kamaguchi, Osterloh, Pigors, Gross, Khil'chenko, Kasprik, Patzelt, Wortmann, Ibrahim, Izumi, Goletz, Boch, Kalies, Bieber, Smith, Schmidt and Ludwig. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases

Saeedeh Ghorbalalipoor<sup>1‡</sup>, Shirin Emtenani<sup>1‡</sup>, Melissa Parker<sup>2</sup>, Mayumi Kamaguchi<sup>1</sup>, Colin Osterloh<sup>1</sup>, Manuela Pigors<sup>1</sup>, Natalie Gross<sup>1</sup>, Stanislav Khil'chenko<sup>1</sup>, Anika Kasprick<sup>1</sup>, Sabrina Patzelt<sup>1</sup>, Diana Wortmann<sup>1</sup>, Ibrahim O. Ibrahim<sup>1</sup>, Kentaro Izumi<sup>1</sup>, Stephanie Goletz<sup>1</sup>, Katharina Boch<sup>3</sup>, Kathrin Kalies<sup>4</sup>, Katja Bieber<sup>1</sup>, Paul Smith<sup>2†</sup>, Enno Schmidt<sup>1§</sup> and Ralf J. Ludwig<sup>1\*§</sup>

<sup>1</sup>Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany, <sup>2</sup>Incyte Research Institute, Wilmington, DE, United States,

<sup>3</sup>Department of Dermatology, University of Lübeck, Lübeck, Germany, <sup>4</sup>Institute of Anatomy, University of Lübeck, Lübeck, Germany

## KEYWORDS

animal model, neutrophils, autoimmunity, pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid, signal transduction, phosphatidylinositol 3-kinase (PI3k)

**A Corrigendum on**

Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases.

by Ghorbalalipoor S, Emtenani S, Parker M, Kamaguchi M, Osterloh C, Pigors M, Gross N, Khil'chenko S, Kasprik A, Patzelt S, Wortmann D, Ibrahim IO, Izumi K, Goletz S, Boch K, Kalies K, Bieber K, Smith P, Schmidt E and Ludwig RJ (2022) *Front. Immunol.* 13:865241. doi: 10.3389/fimmu.2022.865241

In the published article, there was an error in the author list. The equal contribution of Saeedeh Ghorbalalipoor, Shirin Emtenani as first authors and that of Enno Schmidt and Ralf J. Ludwig as last authors had not been indicated. The corrected author list appears below.

Saeedeh Ghorbanalipoor<sup>†</sup>, Shirin Emtenani<sup>‡</sup>, Melissa Parker<sup>2</sup>, Mayumi Kamaguchi<sup>1</sup>, Colin Osterloh<sup>1</sup>, Manuela Pigors<sup>1</sup>, Natalie Gross<sup>1</sup>, Stanislav Khil'chenko<sup>1</sup>, Anika Kasprick<sup>1</sup>, Sabrina Patzelt<sup>1</sup>, Diana Wortmann<sup>1</sup>, Ibrahim O. Ibrahim<sup>1</sup>, Kentaro Izumi<sup>1</sup>, Stephanie Goletz<sup>1</sup>, Katharina Boch<sup>3</sup>, Kathrin Kalies<sup>4</sup>, Katja Bieber<sup>1</sup>, Paul Smith<sup>2†</sup>, Enno Schmidt<sup>1§</sup> and Ralf J. Ludwig<sup>1\*</sup><sup>§</sup>

<sup>†</sup>Present Address: Paul Smith, Connect Biopharma, San Diego, CA, United States

<sup>‡</sup>These authors have contributed equally to this work

<sup>\*</sup>These authors have contributed equally to this work

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.